TY - JOUR
T1 - Metachronous primary gastric cancer after endoscopic resection in patients with esophageal squamous cell carcinoma
AU - Hirao, Motohiro
AU - Katada, Chikatoshi
AU - Yokoyama, Tetsuji
AU - Yano, Tomonori
AU - Suzuki, Haruhisa
AU - Furue, Yasuaki
AU - Yamamoto, Keiko
AU - Doyama, Hisashi
AU - Koike, Tomoyuki
AU - Tamaoki, Masashi
AU - Kawata, Noboru
AU - Kawahara, Yoshiro
AU - Katagiri, Atsushi
AU - Ogata, Takashi
AU - Yamanouchi, Takenori
AU - Kiyokawa, Hirofumi
AU - Kawakubo, Hirofumi
AU - Konno, Maki
AU - Ishikawa, Hideki
AU - Yokoyama, Akira
AU - Muto, Manabu
N1 - Publisher Copyright:
© 2023, The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association.
PY - 2023/11
Y1 - 2023/11
N2 - Background: This study aimed to evaluate the risk factors for developing metachronous primary Gastric Cancer (GC) after Endoscopic Resection (ER) for esophageal Squamous Cell Carcinoma (SCC). Methods: We studied 283 patients with esophageal SCC who underwent ER. The study outcomes were as follows: (1) incidence of metachronous primary GC after ER; and (2) predictors for the development of metachronous primary GC after ER by the Cox proportional hazards model. Results: The median follow-up was 43.1 months (1.81–79.1), and the 3-year cumulative incidence of metachronous primary GC was 6.5% (95%CI: 4.1–10.4). The incidence of metachronous primary GC during the follow-up period was 2.31 per 100 person-years. The frequencies of severe gastric atrophy and macrocytosis at the timing of ER were significantly higher in patients with than without metachronous primary GC (91.7% vs. 73.2%, p = 0.0422, 20.8% vs. 5.2%, p = 0.0046, respectively). Severe gastric atrophy was associated with the development of metachronous primary GC (sex-and-age adjusted hazard ratio (HR) [95%CI] = 4.12 [0.95–27.78], p = 0.0093). Macrocytosis was associated with the development of metachronous primary GC (sex-and-age adjusted HR = 4.76 [1.75–13.0], p = 0.0012) and found to be an independent predictor for metachronous primary GC by multivariate Cox proportional hazards analysis (HR [95%CI] = 4.35 [1.60–11.84], p = 0.004). Conclusions: Severe gastric atrophy and macrocytosis should be noted in the development of metachronous primary GC after ER for esophageal SCC. In particular, macrocytosis at the timing of ER was considered an important predictor. Clinical trials registry number: UMIN000001676.
AB - Background: This study aimed to evaluate the risk factors for developing metachronous primary Gastric Cancer (GC) after Endoscopic Resection (ER) for esophageal Squamous Cell Carcinoma (SCC). Methods: We studied 283 patients with esophageal SCC who underwent ER. The study outcomes were as follows: (1) incidence of metachronous primary GC after ER; and (2) predictors for the development of metachronous primary GC after ER by the Cox proportional hazards model. Results: The median follow-up was 43.1 months (1.81–79.1), and the 3-year cumulative incidence of metachronous primary GC was 6.5% (95%CI: 4.1–10.4). The incidence of metachronous primary GC during the follow-up period was 2.31 per 100 person-years. The frequencies of severe gastric atrophy and macrocytosis at the timing of ER were significantly higher in patients with than without metachronous primary GC (91.7% vs. 73.2%, p = 0.0422, 20.8% vs. 5.2%, p = 0.0046, respectively). Severe gastric atrophy was associated with the development of metachronous primary GC (sex-and-age adjusted hazard ratio (HR) [95%CI] = 4.12 [0.95–27.78], p = 0.0093). Macrocytosis was associated with the development of metachronous primary GC (sex-and-age adjusted HR = 4.76 [1.75–13.0], p = 0.0012) and found to be an independent predictor for metachronous primary GC by multivariate Cox proportional hazards analysis (HR [95%CI] = 4.35 [1.60–11.84], p = 0.004). Conclusions: Severe gastric atrophy and macrocytosis should be noted in the development of metachronous primary GC after ER for esophageal SCC. In particular, macrocytosis at the timing of ER was considered an important predictor. Clinical trials registry number: UMIN000001676.
KW - Endoscopic resection
KW - Esophageal cancer
KW - Gastric cancer
KW - Macrocytosis
KW - Metachronous cancer
UR - http://www.scopus.com/inward/record.url?scp=85162990874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162990874&partnerID=8YFLogxK
U2 - 10.1007/s10120-023-01413-1
DO - 10.1007/s10120-023-01413-1
M3 - Article
C2 - 37368170
AN - SCOPUS:85162990874
SN - 1436-3291
VL - 26
SP - 988
EP - 1001
JO - Gastric Cancer
JF - Gastric Cancer
IS - 6
ER -